Nerve Pain Clinical Trials 2024

Nerve Pain Clinical Trials 2024

Nerve Pain research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in nerve pain clinical trials today.

Nerve Pain Clinical Trials

Here are the 6 most popular medical studies for nerve pain

Popular filter options for nerve pain trials

Diabetic Neuropathy Clinical Trials

View 18 Diabetic Neuropathy medical studies.

Calgary, Alberta

Cannabinoid

Nabilone for Diabetic Neuropathy

Recruiting2 awardsPhase 3
Calgary, Alberta

Neuropathic pain occurs as a result of damage or disease of the peripheral or central nervous system. Regardless of its cause, neuropathic pain (NeP) leads to a characteristic clinical picture characterized by ongoing pain with steady or dysesthetic pain, such as burning or aching, and paroxysmal pain such as shooting or stabbing. In conditions such as diabetic neuropathy, changes in the membrane-bound proteins that form ion channels may alter the electrical properties of the injured neuron, called remodeling. The net effect of membrane remodeling is greater excitability of neurons, leading to a tendency towards action potential generation and propagation in injured primary sensory neurons which occurs in the context of nerve injury and disease. Over the past decade, a new endogenous cannabinoid receptor-mediated system within the nervous system and upon immune-mediated cells has been described. The cannabinoid receptor system consists of two receptors, CB1 and CB2 receptors, as well as endogenously produced endocannabinoids which agonize these receptors. This is a multicenter trial amongst Western Canadian sites to compare the efficacy of nabilone versus placebo in treating patients with chronic neuropathic pain (NeP) due to diabetic peripheral neuropathy (DPN). A one-week screening period will occur, during which pain scores and sleep scores will be tabulated. Following screening, a 4-week period of single blind treatment with flexible dosing of nabilone at 0.5 - 4 mg/day will initiate. All subjects will begin with nabilone therapy of 1 mg daily for a minimum of 4 days, with the dose of the study medication assessed and adjusted either upwards or downwards as needed to balance efficacy for pain control with tolerability of possible side effects. All subjects who experience at least a 30% reduction in their weekly mean pain score during the single blind flexible dosing phase will be considered a responder, and will be further continued in the study. During the double-blind portion of the study, subjects randomized to nabilone will continue on the dose of nabilone achieved at the completion of the single-blind phase, and this dose will be maintained throughout the double-blind phase. Subjects randomized to placebo will receive 1 mg of nabilone daily for one week, followed by 4 consecutive weeks of placebo. This dose of nabilone will permit a tapering for those subjects achieving a higher daily dose of nabilone during the single-blind phase, or will maintain those who were taking only 1 mg per day in the single-blind phase, preventing an abrupt termination of treatment in subjects who are randomized into the placebo portion of the study.

Spinal Cord Injury Clinical Trials

View 15 Spinal Cord Injury medical studies.

Phase 3 Nerve Pain Clinical Trials

View 76 phase 3 nerve pain medical studies.

Calgary, Alberta

Cannabinoid

Nabilone for Diabetic Neuropathy

Recruiting2 awardsPhase 3
Calgary, Alberta

Neuropathic pain occurs as a result of damage or disease of the peripheral or central nervous system. Regardless of its cause, neuropathic pain (NeP) leads to a characteristic clinical picture characterized by ongoing pain with steady or dysesthetic pain, such as burning or aching, and paroxysmal pain such as shooting or stabbing. In conditions such as diabetic neuropathy, changes in the membrane-bound proteins that form ion channels may alter the electrical properties of the injured neuron, called remodeling. The net effect of membrane remodeling is greater excitability of neurons, leading to a tendency towards action potential generation and propagation in injured primary sensory neurons which occurs in the context of nerve injury and disease. Over the past decade, a new endogenous cannabinoid receptor-mediated system within the nervous system and upon immune-mediated cells has been described. The cannabinoid receptor system consists of two receptors, CB1 and CB2 receptors, as well as endogenously produced endocannabinoids which agonize these receptors. This is a multicenter trial amongst Western Canadian sites to compare the efficacy of nabilone versus placebo in treating patients with chronic neuropathic pain (NeP) due to diabetic peripheral neuropathy (DPN). A one-week screening period will occur, during which pain scores and sleep scores will be tabulated. Following screening, a 4-week period of single blind treatment with flexible dosing of nabilone at 0.5 - 4 mg/day will initiate. All subjects will begin with nabilone therapy of 1 mg daily for a minimum of 4 days, with the dose of the study medication assessed and adjusted either upwards or downwards as needed to balance efficacy for pain control with tolerability of possible side effects. All subjects who experience at least a 30% reduction in their weekly mean pain score during the single blind flexible dosing phase will be considered a responder, and will be further continued in the study. During the double-blind portion of the study, subjects randomized to nabilone will continue on the dose of nabilone achieved at the completion of the single-blind phase, and this dose will be maintained throughout the double-blind phase. Subjects randomized to placebo will receive 1 mg of nabilone daily for one week, followed by 4 consecutive weeks of placebo. This dose of nabilone will permit a tapering for those subjects achieving a higher daily dose of nabilone during the single-blind phase, or will maintain those who were taking only 1 mg per day in the single-blind phase, preventing an abrupt termination of treatment in subjects who are randomized into the placebo portion of the study.

Nerve Pain Clinical Trials With No Placebo

View 76 nerve pain medical studies that do not have a placebo group.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to nerve pain

What are the top hospitals conducting nerve pain research?

Nerve pain, also known as neuropathic pain, can be debilitating and challenging to manage. However, leading hospitals across the United States are actively engaged in cutting-edge clinical trials to find innovative solutions for this condition. Stanford University, with its main campus located in Stanford and an additional center in Palo Alto, is paving the way with three ongoing nerve pain trials and a cumulative total of six past studies. Notably, their first recorded nerve pain trial dates back to 2016, demonstrating their commitment to tackling this complex issue.

In sunny Miami, the University of Miami has emerged as a significant player in nerve pain research. With three active clinical trials currently underway and four completed studies under their belt since initiating their first trial in 2017, they are dedicated to advancing understanding and treatment options for individuals experiencing nerve-related discomfort.

Meanwhile, all the way up north in Minneapolis at the University of Minnesota's renowned medical institution lies another hub of innovation when it comes to combating nerve pain. Having conducted five comprehensive trials thus far since embarking on their inaugural study in 2016 while simultaneously engaging with three active ones; they continue making strides towards improving patients' quality of life by addressing this often-agonizing ailment.

Boston's Massachusetts General Hospital rounds out our list but certainly not lacking when it comes to contributions against neuropathic agony. Since conducting its first groundbreaking trial back in2006,todaythey have three ongoing research investigations focused exclusively on tackling nerve pain while having garnered commendable completion recordsof six such tests throughout history.

These esteemed institutions illustrate that there is hope on the horizon for those grappling with unrelenting nerve pain - an affliction that affects countless individuals worldwide. Through pioneering research efforts taking place across these diverse locations nationwide,fresh insightsare continually being gained into this intricate condition.These invaluable initiatives bring us closer than ever before discovering novel treatments aimed at alleviating suffering endured by those affected by chronic neuropathy. With ongoing dedication and breakthroughs, these hospitals are paving the way towards a brighter, pain-free future for individuals grappling with nerve pain.

Which are the best cities for nerve pain clinical trials?

When it comes to nerve pain clinical trials, several cities in the United States stand out as hubs of research and development. Boston, Massachusetts leads the way with 11 active trials investigating treatments like Gabapentin and Qutenza. Houston, Texas follows closely behind with 10 ongoing studies focused on interventions such as Tetrodotoxin for injection. Miami, Florida also plays a significant role in nerve pain research with 8 active trials exploring options like Transcranial direct electrical stimulation. These cities, along with Chicago and New york City, offer individuals suffering from nerve pain opportunities to participate in cutting-edge clinical trials that may lead to improved management and relief of their symptoms.

Which are the top treatments for nerve pain being explored in clinical trials?

Exciting developments in clinical trials are shedding light on the top treatments being explored for nerve pain. [18F]FTC-146, a promising drug, is currently undergoing testing in two active trials dedicated to nerve pain. First introduced in 2018, it has already accumulated an impressive record of two all-time trials focused on tackling this challenging condition. Another notable contender is spinal cord stimulation, with two ongoing trials and a total of five historical studies addressing nerve pain since its introduction in 2014. Lastly, ketamine infusion shows promising potential as a treatment option for nerve pain and is currently being investigated in one active trial after making its first appearance on the scene in 2021. These innovative approaches offer hope for individuals struggling with debilitating nerve pain and may pave the way towards improved quality of life.

What are the most recent clinical trials for nerve pain?

Exciting developments in the field of nerve pain management have emerged from recent clinical trials. Among them, RTA 901, a groundbreaking treatment for nerve pain, has entered Phase 2 testing and shows promise in providing relief. Additionally, Gabapentin and THC (Dronabinol) have both progressed to Phase 3 and Phase 2 respectively as potential therapies for alleviating nerve pain. CBD/PEA is also being explored in Phases 1 and 2 studies with encouraging results thus far. Lastly, AFA-281 has initiated its Phase 1 trial targeting nerve pain management. These advancements signify significant progress towards improved treatments for individuals suffering from this debilitating condition.

What nerve pain clinical trials were recently completed?

Several clinical trials focusing on nerve pain have recently concluded, offering potential advancements in the management of this debilitating condition. In January 2022, Eli Lilly and Company successfully completed a trial investigating LY3526318's efficacy in addressing nerve pain. Preceding this, Lexicon Pharmaceuticals wrapped up their LX9211 trial in December 2020. Furthermore, November 2020 saw the completion of a trial for ETX-018810 conducted by Eliem Therapeutics (UK) Ltd., while Seema Capoor's Naloxone Hydrochloride 0.4 MG/ML study reached its conclusion in October 2020. These recent developments contribute to our understanding and treatment options for nerve pain, signifying progress towards improving patients' quality of life.